{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:47:18Z","timestamp":1791388038901,"version":"4.3.3"},"reference-count":88,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Topical corticosteroids (TCSs) are the most widely used treatment for atopic Dermatitis\u00ae (AD), but they can have adverse effects such as skin atrophy, telangiectasias, and hypopigmentation, especially with prolonged use of higher potency steroids. Many patients also have a fear of using TCSs, known as \u201ccorticophobia.\u201d With the development of biologics and Janus kinase inhibitors, a nonsteroidal approach to the treatment of AD may be possible and may be preferred by certain patients. Given what is known about these nonsteroidal therapies, we propose a structured treatment ladder and action plan that can guide clinicians and patients on the use of these therapies for the treatment of AD. The ladder divides nonsteroidal medication classes into treatments for exacerbation versus maintenance therapies in an escalating order of increasing potential for adverse effects, both real and perceived. This treatment algorithm proposal paves the way for a potential nonsteroidal approach to managing AD.\n                  <\/jats:p>","DOI":"10.1089\/derm.2023.0373","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T16:24:13Z","timestamp":1707236653000},"page":"596-604","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Nonsteroidal Approaches for Atopic Dermatitis\u00ae: A Clinical Update"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-0279","authenticated-orcid":false,"given":"Peter Y.","family":"Ch'en","sequence":"first","affiliation":[{"name":"From the,  Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-0152","authenticated-orcid":false,"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA."},{"name":"Medical Dermatology Associates of Chicago, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"1214963","DOI":"10.3389\/fmed.2023.1214963","article-title":"Anti-inflammatory and biologic drugs for atopic Dermatitis\u00ae: a therapeutic approach in children and adolescents","volume":"10","author":"Caffarelli C","year":"2023","unstructured":"Caffarelli C, , Giannetti A, , Giann\u00ec G, et al. Anti-inflammatory and biologic drugs for atopic Dermatitis\u00ae: a therapeutic approach in children and adolescents. Front Med (Lausanne), 2023; 10:1214963. doi: 10.3389\/fmed.2023.1214963.","journal-title":"Front Med (Lausanne)"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6045"},{"issue":"6","key":"e_1_3_1_4_2","article-title":"Atopic Dermatitis\u00ae: disease features, therapeutic options, and a multidisciplinary approach","volume":"13","author":"Lugovi\u0107-Mihi\u0107 L","year":"2023","unstructured":"Lugovi\u0107-Mihi\u0107 L, , Me\u0161trovi\u0107-\u0160tefekov J, , Poto\u010dnjak I, et al. Atopic Dermatitis\u00ae: disease features, therapeutic options, and a multidisciplinary approach. Life (Basel), 2023; 13(6). doi: 10.3390\/life13061419.","journal-title":"Life (Basel)"},{"key":"e_1_3_1_5_2","volume-title":"StatPearls [Internet]","author":"Kolb L","year":"2023","unstructured":"Kolb L, , Ferrer-Bruker SJ. Atopic Dermatitis\u00ae. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"issue":"3","key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic Dermatitis\u00ae in America Study: a cross-sectional study examining the prevalence and disease burden of atopic Dermatitis\u00ae in the US adult population","volume":"139","author":"Chiesa Fuxench ZC","year":"2019","unstructured":"Chiesa Fuxench ZC, , Block JK, , Boguniewicz M, et al. Atopic Dermatitis\u00ae in America Study: a cross-sectional study examining the prevalence and disease burden of atopic Dermatitis\u00ae in the US adult population. J Invest Dermatol, 2019; 139(3):583\u2013590. doi: 10.1016\/j.jid.2018.08.028.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"e_1_3_1_7_2","article-title":"The epidemiology and global burden of atopic Dermatitis\u00ae: a narrative review","volume":"11","author":"Hadi HA","year":"2021","unstructured":"Hadi HA, , Tarmizi AI, , Khalid KA, et al. The epidemiology and global burden of atopic Dermatitis\u00ae: a narrative review. Life (Basel), 2021; 11(9). doi: 10.3390\/life11090936.","journal-title":"Life (Basel)"},{"issue":"5","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","article-title":"Epidemiology of adult atopic Dermatitis\u00ae","volume":"36","author":"Sacotte R","year":"2018","unstructured":"Sacotte R, , Silverberg JI. Epidemiology of adult atopic Dermatitis\u00ae. Clin Dermatol, 2018; 36(5):595\u2013605. doi: 10.1016\/j.clindermatol.2018.05.007.","journal-title":"Clin Dermatol"},{"issue":"1","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/JDN.0000000000000658","article-title":"Advances in therapy for atopic Dermatitis\u00ae","volume":"14","author":"Zhou N","year":"2022","unstructured":"Zhou N, , Bilimoria S, , Lio PA. Advances in therapy for atopic Dermatitis\u00ae. J Dermatol Nurses' Assoc, 2022; 14(1):36\u201341.","journal-title":"J Dermatol Nurses' Assoc"},{"issue":"2","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.36849\/JDD.7071","article-title":"Burden, control, and treatment of moderate to severe atopic Dermatitis\u00ae in 2021: A United States Patient Survey Study","volume":"22","author":"Lio P","year":"2023","unstructured":"Lio P, , Mackie D, , Bates D, et al. Burden, control, and treatment of moderate to severe atopic Dermatitis\u00ae in 2021: A United States Patient Survey Study. J Drugs Dermatol, 2023; 22(2):119\u2013131. doi: 10.36849\/jdd.7071.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"2222201","DOI":"10.1080\/09546634.2023.2222201","article-title":"Patient preferences for atopic Dermatitis\u00ae treatments: a discrete choice experiment","volume":"34","author":"Kwatra SG","year":"2023","unstructured":"Kwatra SG, , Lio P, , Weidinger S, et al. Patient preferences for atopic Dermatitis\u00ae treatments: a discrete choice experiment. J Dermatol Treat, 2023; 34(1):2222201.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ped4.12400","article-title":"Biologics and oral small-molecule inhibitors for treatment of pediatric atopic Dermatitis\u00ae: Opportunities and challenges","volume":"7","author":"Zhao A","year":"2023","unstructured":"Zhao A, , Pan C, , Li M. Biologics and oral small-molecule inhibitors for treatment of pediatric atopic Dermatitis\u00ae: Opportunities and challenges. Pediatr Investig, 2023; 7(3):177\u2013190. doi: 10.1002\/ped4.12400.","journal-title":"Pediatr Investig"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.029"},{"issue":"2","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5021\/ad.22.114","article-title":"Prescription patterns of topical medications in patients with atopic Dermatitis\u00ae: an investigative review using big data from the National Health Insurance Corporation","volume":"35","author":"Lee J","year":"2023","unstructured":"Lee J, , Kim T, , Cheon SJ, et al. Prescription patterns of topical medications in patients with atopic Dermatitis\u00ae: an investigative review using big data from the National Health Insurance Corporation. Ann Dermatol, 2023; 35(2):124\u2013131. doi: 10.5021\/ad.22.114.","journal-title":"Ann Dermatol"},{"issue":"3","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","article-title":"A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic Dermatitis\u00ae and other dermatoses","volume":"72","author":"Hajar T","year":"2015","unstructured":"Hajar T, , Leshem YA, , Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic Dermatitis\u00ae and other dermatoses. J Am Acad Dermatol, 2015; 72(3):541\u2013549.e2. doi: 10.1016\/j.jaad.2014.11.024.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1080\/09546634.2021.1882659","article-title":"Topical corticosteroid withdrawal (\u2018steroid addiction\u2019): an update of a systematic review","volume":"33","author":"Hwang J","year":"2022","unstructured":"Hwang J, , Lio PA. Topical corticosteroid withdrawal (\u2018steroid addiction\u2019): an update of a systematic review. J Dermatol Treat, 2022; 33(3):1293\u20131298.","journal-title":"J Dermatol Treat"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000387"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15751"},{"issue":"10","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamadermatol.2017.2437","article-title":"Topical corticosteroid phobia in atopic Dermatitis\u00ae: a systematic review","volume":"153","author":"Li AW","year":"2017","unstructured":"Li AW, , Yin ES, , Antaya RJ. Topical corticosteroid phobia in atopic Dermatitis\u00ae: a systematic review. JAMA Dermatol, 2017; 153(10):1036\u20131042. doi: 10.1001\/jamadermatol.2017.2437.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ced\/llac019","article-title":"#corticophobia: a review on online misinformation related to topical steroids","volume":"48","author":"Finnegan P","year":"2022","unstructured":"Finnegan P, , Murphy M, , O'Connor C. #corticophobia: a review on online misinformation related to topical steroids. Clin Exp Dermatol, 2022; 48(2):112\u2013115. doi: 10.1093\/ced\/llac019.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"e_1_3_1_21_2","first-page":"437","article-title":"Breaking through the steroid stigma: a single-centre study on topical corticosteroid perception and adherence in dermatology patients and caregivers","volume":"78","author":"Kew CH","year":"2023","unstructured":"Kew CH, , Ahmad Basir KF, , Low DW, et al. Breaking through the steroid stigma: a single-centre study on topical corticosteroid perception and adherence in dermatology patients and caregivers. Med J Malaysia, 2023; 78(4):437\u2013444.","journal-title":"Med J Malaysia"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1999412"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12887-016-0607-9","article-title":"Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic Dermatitis\u00ae","volume":"16","author":"Siegfried EC","year":"2016","unstructured":"Siegfried EC, , Jaworski JC, , Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic Dermatitis\u00ae. BMC Pediatr, 2016; 16:75. doi: 10.1186\/s12887-016-0607-9.","journal-title":"BMC Pediatr"},{"key":"e_1_3_1_24_2","volume-title":"StatPearls [Internet]","author":"Gabros S","year":"2023","unstructured":"Gabros S, , Nessel TA, , Zito PM. Topical Corticosteroids. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.074"},{"issue":"6","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0301-0546(05)73248-1","article-title":"Rebound phenomenon to systemic corticosteroid in atopic Dermatitis\u00ae","volume":"33","author":"Forte WC","year":"2005","unstructured":"Forte WC, , Sumita JM, , Rodrigues AG, et al. Rebound phenomenon to systemic corticosteroid in atopic Dermatitis\u00ae. Allergol Immunopathol (Madr), 2005; 33(6):307\u2013311. doi: 10.1016\/s0301-0546(05)73248-1.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"5","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1007\/s12325-022-02071-y","article-title":"Prescription market share and treatment patterns in atopic Dermatitis\u00ae: a retrospective observational study using US Insurance Claims","volume":"39","author":"Fenske C","year":"2022","unstructured":"Fenske C, , Boytsov N, , Guo J, et al. Prescription market share and treatment patterns in atopic Dermatitis\u00ae: a retrospective observational study using US Insurance Claims. Adv Ther, 2022; 39(5):2052\u20132064. doi: 10.1007\/s12325-022-02071-y.","journal-title":"Adv Ther"},{"issue":"1","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12875-023-02071-z","article-title":"Topical corticosteroid counselling among Malaysian community pharmacists: a qualitative interview study","volume":"24","author":"Nathan AD","year":"2023","unstructured":"Nathan AD, , Shankar PR, , Sreeramareddy CT. Topical corticosteroid counselling among Malaysian community pharmacists: a qualitative interview study. BMC Prim Care, 2023; 24(1):119. doi: 10.1186\/s12875-023-02071-z.","journal-title":"BMC Prim Care"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/DHPS.S78016","article-title":"Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic Dermatitis\u00ae: a targeted cross-sectional survey","volume":"7","author":"Takahashi-Ando N","year":"2015","unstructured":"Takahashi-Ando N, , Jones MA, , Fujisawa S, et al. Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic Dermatitis\u00ae: a targeted cross-sectional survey. Drug Healthc Patient Saf, 2015; 7:57\u201362. doi: 10.2147\/dhps.S78016.","journal-title":"Drug Healthc Patient Saf"},{"issue":"5","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jaip.2023.03.022","article-title":"A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic Dermatitis\u00ae","volume":"11","author":"Pena J","year":"2023","unstructured":"Pena J, , Zameza PA, , Pixley JN, et al. A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic Dermatitis\u00ae. J Allergy Clin Immunol Pract, 2023; 11(5):1347\u20131359. doi: 10.1016\/j.jaip.2023.03.022.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamapediatrics.2021.0433","article-title":"Association of oral corticosteroid bursts with severe adverse events in children","volume":"175","author":"Yao T-C","year":"2021","unstructured":"Yao T-C, , Wang J-Y, , Chang S-M, et al. Association of oral corticosteroid bursts with severe adverse events in children. JAMA Pediatr, 2021; 175(7):723\u2013729. doi: 10.1001\/jamapediatrics.2021.0433.","journal-title":"JAMA Pediatr"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1415"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.003"},{"issue":"1","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjd.12957","article-title":"Atopic Dermatitis\u00ae\u2014all you can do from the outside","volume":"170","author":"Gelmetti C","year":"2014","unstructured":"Gelmetti C, , Wollenberg A. Atopic Dermatitis\u00ae\u2014all you can do from the outside. Br J Dermatol, 2014; 170(s1):19\u201324. doi: 10.1111\/bjd.12957.","journal-title":"Br J Dermatol"},{"issue":"5","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic Dermatitis\u00ae) in adults and children: part I","volume":"32","author":"Wollenberg A","year":"2018","unstructured":"Wollenberg A, , Barbarot S, , Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic Dermatitis\u00ae) in adults and children: part I. J Eur Acad Dermatol Venereol, 2018; 32(5):657\u2013682. doi: 10.1111\/jdv.14891.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1398-9995.2007.01406.x-i1","article-title":"Proactive treatment of atopic Dermatitis\u00ae in adults with 0.1% tacrolimus ointment","volume":"63","author":"Wollenberg A","year":"2008","unstructured":"Wollenberg A, , Reitamo S, , Atzori F, et al. Proactive treatment of atopic Dermatitis\u00ae in adults with 0.1% tacrolimus ointment. Allergy, 2008; 63(6):742\u2013750. doi: 10.1111\/j.1398-9995.2007.01406.x-i1.","journal-title":"Allergy"},{"issue":"3","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5021\/ad.2012.24.3.253","article-title":"Long term treatment concepts and proactive therapy for atopic eczema","volume":"24","author":"Wollenberg A","year":"2012","unstructured":"Wollenberg A, , Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol, 2012; 24(3):253\u2013260. doi: 10.5021\/ad.2012.24.3.253.","journal-title":"Ann Dermatol"},{"issue":"2","key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1610-0387.2008.06772.x","article-title":"Proactive therapy of atopic eczema\u2014an evidence-based concept with a behavioral background","volume":"7","author":"Wollenberg A","year":"2009","unstructured":"Wollenberg A, , Frank R, , Kroth J, et al. Proactive therapy of atopic eczema\u2014an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges, 2009; 7(2):117\u2013121. doi: 10.1111\/j.1610-0387.2008.06772.x.","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00780-w"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0013-9"},{"issue":"7","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"e15549","DOI":"10.1111\/dth.15549","article-title":"Efficacy and safety profile of antioxidants in the treatment of atopic Dermatitis\u00ae: A systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Yang H","year":"2022","unstructured":"Yang H, , Chen JS, , Luo XY, et al. Efficacy and safety profile of antioxidants in the treatment of atopic Dermatitis\u00ae: A systematic review and meta-analysis of randomized controlled trials. Dermatol Ther, 2022; 35(7):e15549. doi: 10.1111\/dth.15549.","journal-title":"Dermatol Ther"},{"key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"112477","DOI":"10.1016\/j.jep.2019.112477","article-title":"Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis\u00ae: a randomized clinical trial","volume":"250","author":"Lin YK","year":"2020","unstructured":"Lin YK, , Chang SH, , Yang CY, et al. Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis\u00ae: a randomized clinical trial. J Ethnopharmacol, 2020; 250:112477. doi: 10.1016\/j.jep.2019.112477.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1039\/D0FO02091E","article-title":"The anti-allergic potential of tea: a review of its components, mechanisms and risks","volume":"12","author":"Li QS","year":"2021","unstructured":"Li QS, , Wang YQ, , Liang YR, et al. The anti-allergic potential of tea: a review of its components, mechanisms and risks. Food Funct, 2021; 12(1):57\u201369. doi: 10.1039\/d0fo02091e.","journal-title":"Food Funct"},{"issue":"2","key":"e_1_3_1_44_2","first-page":"917","article-title":"Coal tar induces AHR-dependent skin barrier repair in atopic Dermatitis\u00ae","volume":"123","author":"van den Bogaard EH","year":"2013","unstructured":"van den Bogaard EH, , Bergboer JG, , Vonk-Bergers M, et al. Coal tar induces AHR-dependent skin barrier repair in atopic Dermatitis\u00ae. J Clin Invest, 2013; 123(2):917\u2013927. doi: 10.1172\/jci65642.","journal-title":"J Clin Invest"},{"issue":"10","key":"e_1_3_1_45_2","first-page":"1258","article-title":"An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic Dermatitis\u00ae","volume":"9","author":"Slutsky JB","year":"2010","unstructured":"Slutsky JB, , Clark RA, , Remedios AA, et al. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic Dermatitis\u00ae. J Drugs Dermatol, 2010; 9(10):1258\u20131264.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.024"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00647-y"},{"issue":"4","key":"e_1_3_1_48_2","first-page":"5","article-title":"Review of evidence for dietary influences on atopic Dermatitis\u00ae","volume":"19","author":"Mohajeri S","year":"2014","unstructured":"Mohajeri S, , Newman SA. Review of evidence for dietary influences on atopic Dermatitis\u00ae. Skin Ther Lett, 2014; 19(4):5\u20137.","journal-title":"Skin Ther Lett"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0412-3"},{"issue":"5","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-022-00712-0","article-title":"What's new in topicals for atopic Dermatitis\u00ae?","volume":"23","author":"Kleinman E","year":"2022","unstructured":"Kleinman E, , Laborada J, , Metterle L, et al. What's new in topicals for atopic Dermatitis\u00ae?. Am J Clin Dermatol, 2022; 23(5):595\u2013603. doi: 10.1007\/s40257-022-00712-0.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1159\/000508771","article-title":"Pearls in mitigating application pain of topical nonsteroidal agents","volume":"236","author":"Madsen S","year":"2020","unstructured":"Madsen S, , Price Kyla N, , Shi Vivian Y, et al. Pearls in mitigating application pain of topical nonsteroidal agents. Dermatology, 2020; 236(5):477\u2013480. doi: 10.1159\/000508771.","journal-title":"Dermatology"},{"key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.curtheres.2022.100679","article-title":"Safety profile and tolerability of topical phosphodiesterase 4 inhibitors for the treatment of atopic Dermatitis\u00ae: A systematic review and meta-analysis","volume":"96","author":"Mart\u00edn-Santiago A","year":"2022","unstructured":"Mart\u00edn-Santiago A, , Puig S, , Arumi D, et al. Safety profile and tolerability of topical phosphodiesterase 4 inhibitors for the treatment of atopic Dermatitis\u00ae: A systematic review and meta-analysis. Curr Ther Res Clin Exp, 2022; 96:100679. doi: 10.1016\/j.curtheres.2022.100679.","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.03.004"},{"issue":"5","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2500\/aap.2021.42.210064","article-title":"Efficacy and safety of crisaborole in patients with mild-to-moderate atopic Dermatitis\u00ae and other atopic comorbidities","volume":"42","author":"Spergel JM","year":"2021","unstructured":"Spergel JM, , Blaiss MS, , Lio P, et al. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic Dermatitis\u00ae and other atopic comorbidities. Allergy Asthma Proc. 2021; 42(5):425\u2013431. doi: 10.2500\/aap.2021.42.210064","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s13555-021-00584-y","article-title":"Efficacy and safety trends with continuous, long-term crisaborole use in patients aged \u22652 years with mild-to-moderate atopic Dermatitis\u00ae","volume":"11","author":"Geng B","year":"2021","unstructured":"Geng B, , Hebert AA, , Takiya L, et al. Efficacy and safety trends with continuous, long-term crisaborole use in patients aged \u22652 years with mild-to-moderate atopic Dermatitis\u00ae. Dermatol Ther (Heidelb), 2021; 11(5):1667\u20131678. doi: 10.1007\/s13555-021-00584-y.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad188"},{"issue":"3","key":"e_1_3_1_57_2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel C","year":"2023","unstructured":"Samuel C, , Cornman H, , Kambala A, et al. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther (Heidelb), 2023; 13(3):729\u2013749. doi: 10.1007\/s13555-023-00892-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/exd.14753","article-title":"Efficacy and safety of topical JAK inhibitors in the treatment of atopic Dermatitis\u00ae in paediatrics and adults: a systematic review","volume":"32","author":"Sadeghi S","year":"2023","unstructured":"Sadeghi S, , Mohandesi NA. Efficacy and safety of topical JAK inhibitors in the treatment of atopic Dermatitis\u00ae in paediatrics and adults: a systematic review. Exp Dermatol, 2023; 32(5):599\u2013610. doi: 10.1111\/exd.14753.","journal-title":"Exp Dermatol"},{"issue":"12","key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/1346-8138.16126","article-title":"Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic Dermatitis\u00ae: a network meta-analysis","volume":"48","author":"Zhang L","year":"2021","unstructured":"Zhang L, , Du D, , Wang L, et al. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic Dermatitis\u00ae: a network meta-analysis. J Dermatol, 2021; 48(12):1877\u20131883. doi: 10.1111\/1346-8138.16126.","journal-title":"J Dermatol"},{"issue":"2","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic Dermatitis\u00ae with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim BS","year":"2020","unstructured":"Kim BS, , Howell MD, , Sun K, et al. Treatment of atopic Dermatitis\u00ae with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol, 2020; 145(2):572\u2013582. doi: 10.1016\/j.jaci.2019.08.042.","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00690-3"},{"key":"e_1_3_1_62_2","volume-title":"StatPearls [Internet]","author":"Elder AJ","year":"2023","unstructured":"Elder AJ, , Patel P, , Daveluy S. Tapinarof. [Updated 2023 Aug 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"issue":"6","key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.jaad.2020.02.043","article-title":"Adverse event monitoring in patients on oral systemic medications for inflammatory skin disease","volume":"82","author":"Singh P","year":"2020","unstructured":"Singh P, , Silverberg JI. Adverse event monitoring in patients on oral systemic medications for inflammatory skin disease. J Am Acad Dermatol, 2020; 82(6):1537\u20131539. doi: 10.1016\/j.jaad.2020.02.043.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"e_1_3_1_64_2","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1080\/09546634.2022.2038361","article-title":"Use of systemic therapies in adults with atopic Dermatitis\u00ae: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic Dermatitis\u00ae (EUROSTAD)","volume":"33","author":"de Bruin-Weller M","year":"2022","unstructured":"de Bruin-Weller M, , Pink AE, , Ferrucci SM, et al. Use of systemic therapies in adults with atopic Dermatitis\u00ae: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic Dermatitis\u00ae (EUROSTAD). J Dermatolog Treat, 2022; 33(5):2565\u20132570. doi: 10.1080\/09546634.2022.2038361.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/bjd\/ljad222","article-title":"Systemic immunosuppressive therapies for children with refractory atopic Dermatitis\u00ae: a large real-life cohort study","volume":"189","author":"Ollech A","year":"2023","unstructured":"Ollech A, , Lefferdink R, , Sheth A, et al. Systemic immunosuppressive therapies for children with refractory atopic Dermatitis\u00ae: a large real-life cohort study. Br J Dermatol 15 2023; 189(4):492\u2013494. doi: 10.1093\/bjd\/ljad222.","journal-title":"Br J Dermatol"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15126"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-022-01047-w"},{"issue":"5","key":"e_1_3_1_68_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/pds.5586","article-title":"Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic Dermatitis\u00ae","volume":"32","author":"Anand P","year":"2023","unstructured":"Anand P, , Schneeweiss S, , Mostaghimi A, et al. Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic Dermatitis\u00ae. Pharmacoepidemiol Drug Saf, 2023; 32(5):567\u2013576. doi: 10.1002\/pds.5586","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.017"},{"issue":"31","key":"e_1_3_1_70_2","doi-asserted-by":"crossref","first-page":"e34516","DOI":"10.1097\/MD.0000000000034516","article-title":"Efficacy and safety of tralokinumab in the treatment of atopic Dermatitis\u00ae: a systematic review and meta-analysis of randomized controlled trials","volume":"102","author":"Zhao DJ","year":"2023","unstructured":"Zhao DJ, , Huang LM, , Xiao J, et al. Efficacy and safety of tralokinumab in the treatment of atopic Dermatitis\u00ae: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore), 2023; 102(31):e34516. doi: 10.1097\/md.0000000000034516.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jamadermatol.2023.2626","article-title":"Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic Dermatitis\u00ae: a secondary analysis","volume":"159","author":"Merola JF","year":"2023","unstructured":"Merola JF, , Butler DC, , Mark T, et al. Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic Dermatitis\u00ae: a secondary analysis. JAMA Dermatol, 2023; 159:1119\u20131123. doi: 10.1001\/jamadermatol.2023.2626.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"e_1_3_1_72_2","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/jdv.19382","article-title":"Survival, efficacy and safety of tralokinumab after 32 and 52weeks of treatment for moderate-to-severe atopic Dermatitis\u00ae in adults: a multicentre real-world study","volume":"38","author":"Pezzolo E","year":"2024","unstructured":"Pezzolo E, , Schena D, , Gambardella A, et al. Survival, efficacy and safety of tralokinumab after 32 and 52weeks of treatment for moderate-to-severe atopic Dermatitis\u00ae in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol, 2024; 38(1):e11\u2013e13. doi: 10.1111\/jdv.19382.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.029"},{"issue":"3","key":"e_1_3_1_74_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.18176\/jiaci.0906","article-title":"Updated review on treatment of atopic Dermatitis\u00ae","volume":"33","author":"Armario-Hita JC","year":"2023","unstructured":"Armario-Hita JC, , Gal\u00e1n-Guti\u00e9rrez M, , Dodero-Anillo JM, et al. Updated review on treatment of atopic Dermatitis\u00ae. J Investig Allergol Clin Immunol, 2023; 33(3):158\u2013167. doi: 10.18176\/jiaci.0906.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_3_1_75_2","volume-title":"StatPearls [Internet]","author":"Padda IS","year":"2023","unstructured":"Padda IS, , Bhatt R, , Parmar M. Upadacitinib. [Updated 2023 Jun 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023."},{"issue":"16","key":"e_1_3_1_76_2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2217\/imt-2023-0057","article-title":"Abrocitinib for the treatment of atopic Dermatitis\u00ae","volume":"15","author":"L\u00e9 AM","year":"2023","unstructured":"L\u00e9 AM, , Gooderham M, , Torres T. Abrocitinib for the treatment of atopic Dermatitis\u00ae. Immunotherapy, 2023; 15(16):1351\u20131362;. doi: 10.2217\/imt-2023-0057.","journal-title":"Immunotherapy"},{"issue":"11","key":"e_1_3_1_77_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt-2023-0037","article-title":"Upadacitinib for moderate to severe atopic Dermatitis\u00ae","volume":"15","author":"Navarro-Trivi\u00f1o F","year":"2023","unstructured":"Navarro-Trivi\u00f1o F, , Alcantara-Luna S, , Dom\u00ednguez-Cruz J, et al. Upadacitinib for moderate to severe atopic Dermatitis\u00ae. Immunotherapy, 2023; 15(11):799\u2013808. doi: 10.2217\/imt-2023-0037.","journal-title":"Immunotherapy"},{"issue":"6","key":"e_1_3_1_78_2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jaad.2023.08.059","article-title":"Real-world effectiveness and safety of upadacitinib for the treatment of atopic Dermatitis\u00ae in adult patients switched from dupilumab: a multicenter retrospective study","volume":"89","author":"Georgakopoulos JR","year":"2023","unstructured":"Georgakopoulos JR, , Sheka D, , Rankin B, et al. Real-world effectiveness and safety of upadacitinib for the treatment of atopic Dermatitis\u00ae in adult patients switched from dupilumab: a multicenter retrospective study. J Am Acad Dermatol, 2023; 89(6):1308\u20131311. doi: 10.1016\/j.jaad.2023.08.059.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.033"},{"key":"e_1_3_1_80_2","article-title":"The safety of systemic Janus kinase inhibitors in atopic Dermatitis\u00ae: a systematic review and meta-analysis of randomized controlled trials","author":"Yoon S","year":"2023","unstructured":"Yoon S, , Kim K, , Shin K, et al. The safety of systemic Janus kinase inhibitors in atopic Dermatitis\u00ae: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol, 2023. doi: 10.1111\/jdv.19426.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad229"},{"issue":"5","key":"e_1_3_1_82_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic Dermatitis\u00ae: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker AM","year":"2022","unstructured":"Drucker AM, , Morra DE, , Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic Dermatitis\u00ae: update of a living systematic review and network meta-analysis. JAMA Dermatol, 2022; 158(5):523\u2013532. doi: 10.1001\/jamadermatol.2022.0455.","journal-title":"JAMA Dermatol"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1623860"},{"issue":"1","key":"e_1_3_1_84_2","doi-asserted-by":"crossref","first-page":"2215356","DOI":"10.1080\/09546634.2023.2215356","article-title":"Treatment preferences among patients with mild-to-moderate atopic Dermatitis\u00ae","volume":"34","author":"Myers K","year":"2023","unstructured":"Myers K, , Silverberg JI, , Parasuraman S, et al. Treatment preferences among patients with mild-to-moderate atopic Dermatitis\u00ae. J Dermatol Treat, 2023; 34(1):2215356. doi: 10.1080\/09546634.2023.2215356.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"e_1_3_1_85_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s13555-020-00413-8","article-title":"Costs and treatment patterns among patients with atopic Dermatitis\u00ae using advanced therapies in the United States: analysis of a retrospective claims database","volume":"10","author":"Eichenfield LF","year":"2020","unstructured":"Eichenfield LF, , DiBonaventura M, , Xenakis J, et al. Costs and treatment patterns among patients with atopic Dermatitis\u00ae using advanced therapies in the United States: analysis of a retrospective claims database. Dermatol Ther (Heidelb), 2020; 10(4):791\u2013806. doi: 10.1007\/s13555-020-00413-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"e_1_3_1_86_2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jaad.2016.08.029","article-title":"Prescribing success: Developing an integrated prescription and eczema action plan for atopic Dermatitis\u00ae","volume":"75","author":"Sauder MB","year":"2016","unstructured":"Sauder MB, , McEvoy A, , Ramien ML. Prescribing success: Developing an integrated prescription and eczema action plan for atopic Dermatitis\u00ae. J Am Acad Dermatol, 2016; 75(6):1281\u20131283. doi: 10.1016\/j.jaad.2016.08.029.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2143"},{"issue":"1","key":"e_1_3_1_88_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajd.13096","article-title":"The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo: a systematic review of randomised clinical trials","volume":"61","author":"Arora CJ","year":"2020","unstructured":"Arora CJ, , Rafiq M, , Shumack S, et al. The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo: a systematic review of randomised clinical trials. Australas J Dermatol, 2020; 61(1):e1\u2013e9. doi: 10.1111\/ajd.13096.","journal-title":"Australas J Dermatol"},{"issue":"12","key":"e_1_3_1_89_2","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.jid.2022.05.1093","article-title":"Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo","volume":"142","author":"Pandya AG","year":"2022","unstructured":"Pandya AG, , Harris JE, , Lebwohl M, et al. Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo. J Investig Dermatol, 2022; 142(12):3352\u20133355.e4.","journal-title":"J Investig Dermatol"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2023.0373","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0373","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2023.0373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:08:48Z","timestamp":1777399728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2023.0373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["10.1089\/derm.2023.0373"],"URL":"https:\/\/doi.org\/10.1089\/derm.2023.0373","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}